The prognosis of patients with EGFR‐ and ALK‐positive NSCLC has significantly improved following treatment with EGFR tyrosine kinase inhibitors (EGFR‐TKIs) and ALK–TKIs, respectively. This evidence concerns the gene ALK and non-small cell lung carcinoma.